FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056317617> ?p ?o ?g. }

• W2056317617 endingPage "177" @default.
• W2056317617 startingPage "159" @default.
• W2056317617 abstract "Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. This review summarizes the existing data published for ceftazidime-avibactam, including relevant chemistry, mechanisms of action and resistance, microbiology, pharmacokinetics, pharmacodynamics, and efficacy and safety data from animal and human trials. Although not a β-lactam, the chemical structure of avibactam closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to β-lactamases. Very little is known about the potential for avibactam to select for resistance. The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzyme(s). Against Pseudomonas aeruginosa, the addition of avibactam also improves the activity of ceftazidime (~fourfold MIC reduction). Limited data suggest that the addition of avibactam does not improve the activity of ceftazidime versus Acinetobacter species or most anaerobic bacteria (exceptions: Bacteroides fragilis, Clostridium perfringens, Prevotella spp. and Porphyromonas spp.). The pharmacokinetics of avibactam follow a two-compartment model and do not appear to be altered by the co-administration of ceftazidime. The maximum plasma drug concentration (Cmax) and area under the plasma concentration-time curve (AUC) of avibactam increase linearly with doses ranging from 50 mg to 2,000 mg. The mean volume of distribution and half-life of 22 L (~0.3 L/kg) and ~2 hours, respectively, are similar to ceftazidime. Like ceftazidime, avibactam is primarily renally excreted, and clearance correlates with creatinine clearance. Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftazidime alone. Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates. The safety and tolerability of ceftazidime-avibactam has been reported in three phase I pharmacokinetic studies and two phase II clinical studies. Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date. In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus ß-lactamase-producing Gram-negative bacilli. The exact roles for ceftazidime-avibactam will be defined by efficacy and safety data from further clinical trials. Potential future roles for ceftazidime-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases. In addition, ceftazidime-avibactam may be used in combination (with metronidazole) for suspected polymicrobial infections. Finally, the increased activity of ceftazidime-avibactam versus P. aeruginosa may be of clinical benefit in patients with suspected or documented P. aeruginosa infections." @default.
• W2056317617 created "2016-06-24" @default.
• W2056317617 creator A5019419595 @default.
• W2056317617 creator A5029310317 @default.
• W2056317617 creator A5033454548 @default.
• W2056317617 creator A5034066865 @default.
• W2056317617 creator A5048093298 @default.
• W2056317617 creator A5048766617 @default.
• W2056317617 creator A5051398176 @default.
• W2056317617 creator A5060268903 @default.
• W2056317617 creator A5061522332 @default.
• W2056317617 creator A5063258446 @default.
• W2056317617 creator A5077464470 @default.
• W2056317617 creator A5090227234 @default.
• W2056317617 date "2013-02-01" @default.
• W2056317617 modified "2023-10-10" @default.
• W2056317617 title "Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination" @default.
• W2056317617 cites W1861263514 @default.
• W2056317617 cites W1963484257 @default.
• W2056317617 cites W1973968673 @default.
• W2056317617 cites W1976073891 @default.
• W2056317617 cites W1987390640 @default.
• W2056317617 cites W1996960109 @default.
• W2056317617 cites W1998311178 @default.
• W2056317617 cites W2006629833 @default.
• W2056317617 cites W2010016959 @default.
• W2056317617 cites W2011167496 @default.
• W2056317617 cites W2013112438 @default.
• W2056317617 cites W2018229558 @default.
• W2056317617 cites W2026414172 @default.
• W2056317617 cites W2038014160 @default.
• W2056317617 cites W2045211463 @default.
• W2056317617 cites W2052779789 @default.
• W2056317617 cites W2054730194 @default.
• W2056317617 cites W2062362165 @default.
• W2056317617 cites W2068735589 @default.
• W2056317617 cites W2074669461 @default.
• W2056317617 cites W2077360598 @default.
• W2056317617 cites W2078776320 @default.
• W2056317617 cites W2079342481 @default.
• W2056317617 cites W2086705273 @default.
• W2056317617 cites W2097533517 @default.
• W2056317617 cites W2098977979 @default.
• W2056317617 cites W2100232903 @default.
• W2056317617 cites W2103929713 @default.
• W2056317617 cites W2105999876 @default.
• W2056317617 cites W2109730521 @default.
• W2056317617 cites W2111516721 @default.
• W2056317617 cites W2116800779 @default.
• W2056317617 cites W2119926695 @default.
• W2056317617 cites W2121581779 @default.
• W2056317617 cites W2126873899 @default.
• W2056317617 cites W2128484737 @default.
• W2056317617 cites W2133786572 @default.
• W2056317617 cites W2134352676 @default.
• W2056317617 cites W2135088547 @default.
• W2056317617 cites W2137527487 @default.
• W2056317617 cites W2143074601 @default.
• W2056317617 cites W2143874510 @default.
• W2056317617 cites W2152127318 @default.
• W2056317617 cites W2153732335 @default.
• W2056317617 cites W2157019531 @default.
• W2056317617 cites W2159995402 @default.
• W2056317617 cites W2161064937 @default.
• W2056317617 cites W2171447404 @default.
• W2056317617 cites W2318497019 @default.
• W2056317617 cites W2322153556 @default.
• W2056317617 doi "https://doi.org/10.1007/s40265-013-0013-7" @default.
• W2056317617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23371303" @default.
• W2056317617 hasPublicationYear "2013" @default.
• W2056317617 type Work @default.
• W2056317617 sameAs 2056317617 @default.
• W2056317617 citedByCount "334" @default.
• W2056317617 countsByYear W20563176172013 @default.
• W2056317617 countsByYear W20563176172014 @default.
• W2056317617 countsByYear W20563176172015 @default.
• W2056317617 countsByYear W20563176172016 @default.
• W2056317617 countsByYear W20563176172017 @default.
• W2056317617 countsByYear W20563176172018 @default.
• W2056317617 countsByYear W20563176172019 @default.
• W2056317617 countsByYear W20563176172020 @default.
• W2056317617 countsByYear W20563176172021 @default.
• W2056317617 countsByYear W20563176172022 @default.
• W2056317617 countsByYear W20563176172023 @default.
• W2056317617 crossrefType "journal-article" @default.
• W2056317617 hasAuthorship W2056317617A5019419595 @default.
• W2056317617 hasAuthorship W2056317617A5029310317 @default.
• W2056317617 hasAuthorship W2056317617A5033454548 @default.
• W2056317617 hasAuthorship W2056317617A5034066865 @default.
• W2056317617 hasAuthorship W2056317617A5048093298 @default.
• W2056317617 hasAuthorship W2056317617A5048766617 @default.
• W2056317617 hasAuthorship W2056317617A5051398176 @default.
• W2056317617 hasAuthorship W2056317617A5060268903 @default.
• W2056317617 hasAuthorship W2056317617A5061522332 @default.
• W2056317617 hasAuthorship W2056317617A5063258446 @default.
• W2056317617 hasAuthorship W2056317617A5077464470 @default.
• W2056317617 hasAuthorship W2056317617A5090227234 @default.
• W2056317617 hasBestOaLocation W20563176172 @default.

• next